4--12% of acute myeloid leukemia (AML) patients present with a translocation between chromosomes 8 and 21 ([@bib17]). However, transgenic mice expressing AML1-ETO only develop AML after treatment with mutagenic agents, suggesting a requirement for cooperating events ([@bib8]). Two mouse models of AML1-ETO--driven AML have been generated that may depend on the acquisition of such events for leukemogenesis. Expression of AML1-ETO in *Cdkn1a*-null cells or expression of AML1-ETO9a, a splice variant of AML1-ETO, in WT cells can induce fully penetrant AML after a prolonged latency ([@bib25]; [@bib20]). *CDKN1A* has never been found to be disrupted in t(8;21)^+^ AML ([@bib22]), suggesting that its loss does not functionally cooperate with AML1-ETO. Instead, it is thought that loss of CDKN1A in vivo prevents the repair of damaged DNA and allows for the accumulation of mutations and cooperating alleles in AML1-ETO^+^ hematopoietic progenitors ([@bib14]). Studies of AML1-ETO9a--driven leukemia have found dysregulated expression of DNA repair genes ([@bib1]), which might facilitate a similar acquisition of cooperating secondary events. We hypothesized that we could identify and credential disease alleles in t(8;21)^+^ AML through integrative genomic studies of human AML and the mouse AMLs that arise from these models.

RESULTS AND DISCUSSION {#s01}
======================

Identification of phenotypically similar mouse models of t(8;21)^+^ AML {#s02}
-----------------------------------------------------------------------

We first expressed AML1-ETO or AML1-ETO9a in fetal liver cells isolated from WT or *Cdkn1a^−/−^* mice. All transplant recipients of AML1-ETO--expressing *Cdkn1a^−/−^* cells developed lethal AML with a median latency of 201 d. Expression of AML1-ETO9a in WT or *Cdkn1a^−/−^* cells resulted in a fully penetrant, lethal leukemia after a median latency of 175 and 196 d, respectively ([Fig. 1 A](#fig1){ref-type="fig"}). At euthanasia, leukemic mice had anemia, thrombocytopenia, and elevated white blood cell counts ([Fig. 1 B](#fig1){ref-type="fig"}). We observed blast cell accumulation in the bone marrow, liver, and spleen, resulting in splenomegaly ([Fig. 1, C and D](#fig1){ref-type="fig"}). The GFP^+^ blast cells display an immature immunophenotype; they are negative for lineage markers and SCA-1 but are c-KIT and MPO positive ([Fig. 1 E](#fig1){ref-type="fig"} and not depicted). Leukemia with an identical immunophenotype develops within secondary recipients ([Fig. 1 F](#fig1){ref-type="fig"} and not depicted). The observations that these mouse models are phenotypically similar and develop AML with similar penetrance and latency suggest that they have acquired similar secondary events.

![**Mouse models of AML1-ETO--driven leukemogenesis are phenotypically similar.** (A) Kaplan-Meier plot of mouse survival after transplantation with cells transduced with the given vector. WT pBEX (*n* = 12); WT AE9a (AML1-ETO9a; *n* = 17); WT AE (AML1-ETO; *n* = 17); *Cdkn1a^−/−^* pBEX (*n* = 11); *Cdkn1a^−/−^* AE9a (*n* = 10); *Cdkn1a^−/−^* AE (*n* = 12). (B) Peripheral blood counts of leukemic mice (from left to right, *n* = 8, *n* = 9, and *n* = 10) and controls (*n* = 5). Horizontal bars represent mean. (C) Representative hematoxylin and eosin staining (*n* = 3). Bars, 50 µm. (D) At euthanasia, leukemic mice exhibit significant splenomegaly compared with controls. WT pBEX (*n* = 2); WT AE9a (*n* = 8); *Cdkn1a^−/−^* AE9a (*n* = 5); *Cdkn1a^−/−^* AE (*n* = 7). Error bars represent the standard deviation from the mean. (B and D) P-values were generated using the Student\'s *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*\*, P \< 0.0001; n.s., not significant. (E) Representative flow cytometry analysis of the bone marrow of transplant recipients (*n* = 10). (F) Kaplan-Meier plot of mouse survival after transplantation with 2 × 10^6^ leukemic spleen cells. WT AE9a (*n* = 15); *Cdkn1a^−/−^* AE9a (*n* = 13); *Cdkn1a^−/−^* AE (*n* = 15).](JEM_20150524_Fig1){#fig1}

Mouse models of AML reproduce the genomic landscape of human AML {#s03}
----------------------------------------------------------------

We next investigated the mutational landscape of the mouse AMLs and compared it with somatic mutational analyses of other mouse AML models and AML patients ([@bib23]; [@bib3]). We did not observe a significant difference in the number of variants detected or genes targeted in the mouse models compared with AML patient samples ([Fig. 2, A--C](#fig2){ref-type="fig"}). When we restricted our analysis to genes for which human--mouse orthology is known, we observed a significant enrichment in mouse AML for specific genes (hypergeometric P ≤ 4.26 × 10^−20^; [Fig. 2 D](#fig2){ref-type="fig"}) and protein domains (hypergeometric P ≤ 4.23 × 10^−3^) mutated in human AML. The domains mutated in both human and mouse AML were similarly affected by recurrent mutations (Spearman correlation of domain p-values r = 0.53, P ≤ 2.73 × 10^−8^; [Fig. 2 E](#fig2){ref-type="fig"}). We next investigated the frequency of mutations in different protein classes and found no differences in the protein classes targeted in AML1-ETO/AML1-ETO9a mouse AML versus human t(8;21)^+^ AML (P = 0.327; [Fig. 2 F](#fig2){ref-type="fig"}).

![**Mouse AML reflects the mutational landscape of human AML.** (A--C) The number of nonsynonymous mutations (A), insertion and deletion events (B), and the number of genes harboring nonsynonymous, insertion, or deletion events in leukemic mice and human AML patients (C). Horizontal bars represent mean. (D) A stacked plot of the genes that are mutated in ≥2% of human AML samples and ≥8% of mouse AML samples. 67.90% of genes mutated in leukemic mice are also mutated in human AML patients, whereas only 5.07% of genes with a protein-coding mutation in AML patients are also mutated in leukemic mice. This enrichment is significant (hypergeometric P ≤ 4.26 × 10^−20^). (E) Of the genes that harbor protein-coding mutations in both leukemic mice and human AML patients, the fraction of protein domains that are mutated in both species (red) or in only one species (blue) is depicted. The color intensity increases with the number of mutations in a given protein domain. 65.07% of these protein domains are mutated in both species, demonstrating enrichment (hypergeometric P ≤ 4.23 × 10^−3^). Domains similarly affected are recurrently mutated (Spearman correlation of domain p-values r = 0.53, binomial P ≤ 2.73 × 10^−8^). (F) The frequencies with which various protein classes are mutated in t(8;21)^+^ mouse and human AML are not significantly different (P = 0.327, a transformed value of the Pillai-Bartlett statistic from a MANOVA model).](JEM_20150524_Fig2){#fig2}

Integrated genomic approach identifies potential cooperating events in t(8;21)^+^ AML {#s04}
-------------------------------------------------------------------------------------

We next sought to mine the mutational data to identify mutations capable of cooperating with AML1-ETO, focusing our efforts on the 424 genes mutated in both human and mouse AML and then further narrowing our focus to those genes that were also significantly mutated (defined as Genome MuSiC significantly mutated gene \[SMG\] false discovery rate \[FDR\] ≤ 30%). This reduced the number of potential candidates from 424 to 38 human genes, representing 45 mouse orthologues ([Fig. 3 A](#fig3){ref-type="fig"}). We focused on the mouse orthologues that were significantly mutated (FDR ≤ 10%) in AML1-ETO--driven leukemias, and not in MLL-AF9--driven leukemia, and identified 38 mouse genes that met these criteria ([Fig. 3 B](#fig3){ref-type="fig"}). These 38 genes correspond to 32 human orthologues, which include three alleles annotated in COSMIC as cancer genes ([@bib7]): *TET2*, *PTPN11*, and *THRAP3*.

![**SMGs in mouse AML identify SMGs in human AML that are potential AML1-ETO cooperating partners.** (A) The patients that harbor nonsynonymous mutations in genes that are significantly mutated in human AML (FDR ≤ 30%). (B) For the genes significantly mutated in human AML, the types of mutations present in mouse AML samples are depicted. Those genes that are significantly mutated in a given mouse AML group (FDR ≤ 10%) are highlighted in blue under the given group. (C) *TET2* mutations identified in t(8;21)^+^ AML patients. (D) *PTPN11* mutations identified in AML patients.](JEM_20150524_Fig3){#fig3}

Expression of AML1-ETO in *Tet2*-null cells generates a novel model of t(8;21)^+^ AML {#s05}
-------------------------------------------------------------------------------------

The variants detected in *TET2* in AML patients include nonsense, frameshift, and missense mutations within conserved domains, consistent with loss of TET2 enzymatic function ([Table S1](http://www.jem.org/cgi/content/full/jem.20150524/DC1){#supp1}). Notably, 3 of the 29 t(8;21)^+^ AML patients enrolled in the ECOG E1900 trial ([@bib18]) harbored *TET2* mutations ([Fig. 3 C](#fig3){ref-type="fig"} and [Table S2](http://www.jem.org/cgi/content/full/jem.20150524/DC1){#supp2}). In vivo, monoallelic or biallelic loss of *Tet2* in the hematopoietic compartment of mice results in myeloproliferation and extramedullary hematopoiesis but not AML ([@bib11]; [@bib16]).

To determine whether loss of *Tet2* can cooperate with AML1-ETO in vivo, we transduced bone marrow cells from *Vav-Cre^+^Tet2^f/f^* (*Tet2* KO) mice with AML1-ETO or AML1-ETO9 and transplanted the cells into lethally irradiated recipients. Mice transplanted with AML1-ETO--expressing *Tet2* KO cells developed fully penetrant leukemia, whereas mice transplanted with AML1-ETO9a--expressing *Tet2* KO cells developed a significantly accelerated leukemia with a median latency of 118 d (P \< 0.0001; [Fig. 4 A](#fig4){ref-type="fig"}). At euthanasia, leukemic recipients had anemia, thrombocytopenia, elevated white blood cell counts ([Fig. 4 B](#fig4){ref-type="fig"}), and blast cell infiltration into the liver and spleen, with consequent splenomegaly ([Fig. 4, C and D](#fig4){ref-type="fig"}). The GFP^+^ blast cells are lineage negative, SCA-1 positive or negative, and c-Kit positive ([Fig. 4 E](#fig4){ref-type="fig"}).

![***Tet2* loss cooperates with AML1-ETO to induce leukemia in vivo.** (A) Kaplan-Meier plot of mouse survival after transplantation with cells transduced with the given vector. WT pBEX (*n* = 5); WT AE (*n* = 10); WT AE9a (*n* = 7); *Tet2* KO pBEX (*n* = 12); *Tet2* KO AE (*n* = 23); *Tet2* KO AE9a (*n* = 13). *Tet2* loss significantly accelerates AE9a leukemias (P \< 0.0001 using the Log-rank test). (B) Peripheral blood counts of mice transplanted with *Tet2* KO cells expressing AE9a (*n* = 10), AE (*n* = 10), or pBEX (*n* = 5). Horizontal bars represent mean. (C) Representative hematoxylin and eosin staining (*n* = 3). Bars, 50 µm. (D) At euthanasia, leukemic mice exhibit significant splenomegaly compared with controls. *Tet2* KO pBEX (*n* = 2); *Tet2* KO AE (*n* = 9); *Tet2* KO AE9a (*n* = 9). Error bars represent the standard deviation from the mean. (B and D) P-values were generated using the Student's *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001. (E) Representative flow cytometry analysis of the bone marrow of transplant recipients (*n* = 10).](JEM_20150524_Fig4){#fig4}

The observed cooperativity between *Tet2* loss and AML1-ETO in vivo implicates *TET2* loss-of-function mutations in t(8;21)^+^ AML patients as functional cooperating events and challenges the traditional "two-hit hypothesis" of AML, which posits that AML1-ETO commonly cooperates with events that activate oncogenic signaling ([@bib10]). Our data support an expanded version of this hypothesis, in which a third class of events capable of enhancing self-renewal are capable of cooperating with AML1-ETO. Given that neomorphic mutations in IDH1/2 and loss-of-function mutations in WT1 also attenuate TET2 function and reduce DNA hydroxymethylation in vivo ([@bib6]; [@bib21]), it will be important to determine whether altered DNA hydroxymethylation is a common pathogenetic event in AML1-ETO^+^ AML and whether AML1-ETO^+^ leukemias with concurrent mutations in epigenetic regulators have a distinct epigenetic profile and/or a distinct response to epigenetic therapies.

Expression of AML1-ETO with PTPN11 D61Y generates a novel model of t(8;21)^+^ AML {#s06}
---------------------------------------------------------------------------------

The PTPN11 mutations that we observe in human and mouse AML occur within highly conserved regions of PTPN11 critical to phosphatase activity and the stimulation of RAS signaling ([Fig. 3 D](#fig3){ref-type="fig"} and [Table S3](http://www.jem.org/cgi/content/full/jem.20150524/DC1){#supp3}; [@bib26]). Previous studies have shown that mice expressing the constitutively active D61Y mutation (*Ptpn11^D61Y^*) develop a fatal myeloproliferative neoplasm. However, bone marrow cells from these mice fail to engraft beyond 20 wk in transplant recipients and do not induce AML ([@bib4]). We therefore transduced bone marrow cells from *Ptpn11^D61Y^* mice with AML1-ETO and transplanted the cells into lethally irradiated recipients. Mice expressing both alleles developed fatal AML ([Fig. 5 A](#fig5){ref-type="fig"}). At euthanasia, leukemic mice had elevated white blood cell counts, anemia, thrombocytopenia ([Fig. 5 B](#fig5){ref-type="fig"}), and blast cell accumulation in the bone marrow, liver, and spleen ([Fig. 5, C and D](#fig5){ref-type="fig"}). These GFP^+^ blasts were Sca-1 negative and c-Kit positive ([Fig. 5 E](#fig5){ref-type="fig"}) and capable of transmitting the disease into secondary recipients (not depicted).

![**PTPN11 D61Y cooperates with AML1-ETO to induce leukemia in vivo.** (A) Kaplan-Meier plot of mouse survival after transplantation with cells transduced with the given vector. WT pBEX (*n* = 10); WT AE (*n* = 15); PTPN11 D61Y pBEX (*n* = 10); PTPN11 D61Y AE (*n* = 15). (B) Peripheral blood counts at euthanasia of leukemic PTPN11 D61Y AE mice (*n* = 5), as well as controls (from left to right, *n* = 10, *n* = 15, and *n* = 10). Horizontal bars represent mean. P-values were generated using the Student's *t* test: \*, P \< 0.05; \*\*\*\*, P \< 0.0001; n.s., not significant. (C) Representative hematoxylin and eosin staining (*n* = 3). Bars, 50 µm. (D) At euthanasia, leukemic mice exhibit splenomegaly. From top to bottom: liver, kidney, and spleen. (E) Representative flow cytometry analysis of the bone marrow of transplant recipients (*n* = 3).](JEM_20150524_Fig5){#fig5}

The observation that AML1-ETO can cooperate with PTPN11 D61Y is more consistent with the two-hit hypothesis and implicates a novel member of the RAS signaling cascade in leukemogenesis. Although RAS mutations occur in 8--10% of AML1-ETO^+^ AML patients ([@bib19]), PTPN11 mutations may be a rare event ([@bib12]). Previous studies pairing AML1-ETO with activating RAS mutations in vivo have had mixed results (Flotho, C. et al. 2004. 46th Annual Meeting of the American Society of Hematology. Poster \#770-II; [@bib5]; [@bib27]). Our data showing that PTPN11 D61Y is capable of cooperating with AML1-ETO suggests that MAPK-directed therapies should be investigated in these genetically defined t(8;21)^+^ AML subsets.

In each of these newly developed mouse models of AML1-ETO--driven AML, the possibility remains that a third hit has been acquired that is necessary for disease initiation. Fortunately, our integrated approach can be applied to these leukemias such that those events are identified and credentialed in an iterative manner. Like previous studies in mouse solid tumors ([@bib13]) and acute promyelocytic leukemia ([@bib24]), our data suggest that systematic comparisons of mutational patterns in mouse and human malignancies represent a powerful means of identifying cooperating disease alleles with mechanistic and therapeutic relevance.

MATERIALS AND METHODS {#s07}
=====================

 {#s08}

### Construction of expression vectors and virus production {#s09}

The cDNAs encoding AML1-ETO or AML1-ETO9a were digested with NotI and cloned into the NotI multiple cloning site of the MSCV-IRES-BEX plasmid (pBEX), upstream of the IRES and blue-excited GFP motifs. pBEX differs from the previously described MigR1 plasmid by featuring cDNA for enhanced GFP that has been altered such that it can be distinguished from violet-excited GFP ([@bib2]). To produce retrovirus capable of expressing AML1-ETO or AML1-ETO9a, 293T cells were cotransfected with a pBEX plasmid and MCV-Ecopac via calcium phosphate precipitation.

### Fetal liver and bone marrow transduction and transplantation {#s10}

Fetal liver cells were harvested from embryonic day (E) 14.5 WT (The Jackson Laboratory) or *Cdkn1a^−/−^* (provided by T. Jacks, The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA) C57BL/6 embryos, whereas bone marrow cells from adult *Vav-Cre^+^* or *Vav-Cre^+^Tet2^f/f^* C57BL/6 mice ([@bib16]) were harvested 6 d after intraperitoneal administration of 200 mg/kg 5-fluorouracil (Sigma-Aldrich). Bone marrow cells were harvested from 9-wk-old *Mx1-Cre^+^* or *Ptpn11^D61Y^* mice that had been treated at 3 wk with poly(I:C) as previously published ([@bib4]). Harvested cells were cultured in RPMI media supplemented with 10% fetal bovine serum, 10 ng/ml IL-3, 10 ng/ml IL-6, and 100 ng/ml stem cell factor (PeproTech) before transplantation, with 8 µg/ml polybrene (Sigma-Aldrich) added during spinoculation. Transduced cells were transplanted into 8--10-wk-old female C57BL/6 recipient mice by tail vein injection after the recipient mice had been lethally irradiated with 950 cGy, given in a split dose separated by 3 h. Procedures performed on these mice were approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center.

### Exome sequencing {#s11}

Genomic DNA from GFP^+^ mouse spleen cells or mouse tail tissue was isolated using phenol-chloroform extraction. Exome capture was performed using the SureSelect Mouse All Exon kit (Agilent Technologies), and sequencing was performed using an Illumina platform. Approximately 80 million reads per sample were acquired after a paired-end run with 75 or 100 bp. Paired-end reads were aligned to the NCBIM37.67/mm9 mouse reference genome using the Burrows-Wheeler Aligner (BWA) aln v0.6.2 and processed using the best practices pipeline that included marking of duplicate reads by the use of Picard tools and realignment around indels and base recalibration via Genome Analysis Toolkit (GATK) v3.1.1. Somatic single nucleotide variants (SNVs) were called using muTect v1.1.4, Virmid v1.1.0, and Strelka v1.0.12 and somatic indels via SomaticIndelDetector v2.3.9 and Strelka. SNVs and indels were filtered using the default filtering criteria as implemented in each of the callers and annotated via snpEff and snpSift. In addition, all germline SNVs and indels identified in the 17 key mouse strains as part of the Mouse Genome Project ([@bib9]) were filtered out of the call set. To compare our results with what has been previously discovered in human patients, we downloaded the BAM files for the 150 human AML exomes from The Cancer Genome Atlas project ([@bib3]). For consistency, we extracted the reads from human exomes, reprocessed them, and called somatic variants using the same pipeline as for mouse exomes.

### SMGs and domain analysis {#s12}

SMGs were identified in mouse and human samples using the SMG module from Genome MuSiC v0.4. Homology between mouse and human genes was based on the mouse--human homologue list downloaded from The Jackson Laboratory website. FDRs were determined using the likelihood ratio test from the Genome MuSiC SMG module. We annotated proteins with protein domains from Pfam-A, a database of high-quality, manually curated protein families. We used the hmmscan algorithm from HMMER3.0 package to match protein sequences against the Pfam-A database.

### Statistical analysis {#s13}

Statistical significance between two groups was assessed using the Student's *t* test with Welch's correction: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001; n.s., not significant. The hypergeometric test was used to determine whether there was significant overlap in the genes that were mutated in mouse and human AML, as well as whether there was significant overlap in the protein domains that were affected in genes mutated in both mouse and human AML. The significance of recurrently mutated protein domains was determined using the binomial test, where p = length of domain (in AA)/length of protein (in AA). To determine whether mouse leukemias were significantly different from human leukemias with respect to the frequency with which all protein classes were affected by gene mutations, protein classes annotated using PANTHER ([@bib15]) were compared across the two groups using the Pillai-Bartlett statistic from a multivariate ANOVA (MANOVA) model. The corresponding p-values were computed from a transformed value of the test statistic which has an approximate F distribution. All calculations were performed using R version 3.0.

### Flow cytometry {#s14}

To determine the immunophenotype of normal and leukemic populations, cells were stained with a panel of antibodies against lineage markers, each of which was conjugated to APC-Cy7: CD3, CD4, CD11b, CD19, CD45R, Gr-1, NK1.1, and TER119. Cells were also stained with anti-CD117 (c-KIT) and anti--SCA-1, conjugated to PE and PE-Cy7, respectively (BioLegend). Stained cells were analyzed using an LSR Fortessa or LSR II flow cytometer (BD), and data were analyzed using FlowJo software.

### Online supplemental material {#s15}

Table S1 lists the *TET2* mutations identified in AML patients from studies by the [@bib3] and [@bib18]. Table S2 provides statistics on the *TET2* mutations identified in AML patients from the [@bib18] study. Table S3 lists the *PTPN11* mutations identified in AML patients from the [@bib3] study. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20150524/DC1>.
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